



Lorbrena in the UAE

The MOHAP named-patient coordination pathway — indicative 2026

ONCOLOGY · ALK-REARRANGED NSCLC

The clinical situation

Lorbrena (lorlatinib) is a third-generation oral ALK tyrosine kinase inhibitor designed to overcome resistance mutations and cross the blood-brain barrier for CNS disease control. Manufactured by Pfizer. Eligibility requires molecular confirmation of an ALK rearrangement; dosing is typically 100 mg once daily continuously, with monitoring for CNS effects (mood, cognition, sleep), hyperlipidaemia, and oedema.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating oncologist confirms ALK status and documents a written clinical rationale and line history.
- 2 Administering facility confirmed.** A UAE tertiary oncology centre with an importing pharmacy is identified.
- 3 MOHAP named-patient application.** Clinical rationale, patient reference, product details, and chain-of-custody plan are filed.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner.
- 5 Arrival & administration.** The pharmacy releases product against prescription; concierge coordinates monthly re-supply ahead of cycle end.

Indicative economics

Reference US cash-pay range: USD 21,000–24,000 per 30-day supply. Logistics, MOHAP documentation, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete MOHAP application to first delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and MOHAP review. **Logistics.** Temperature- and chain-of-custody-compliant shipment. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Lorbrena × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/lorbrena-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team